LOQTORZI 240 mg/6mL
toripalimab-tpzi · INJECTION · Coherus Oncology, Inc.
No Recall History
Plain English
LOQTORZI is a injection containing toripalimab-tpzi at 240 mg/6mL, taken intravenous. Manufactured by Coherus Oncology, Inc..
Key Facts
- Brand Name
- LOQTORZI
- Generic Name
- toripalimab-tpzi
- NDC Code (Product)
70114-340- Manufacturer
- Coherus Oncology, Inc.
- Strength
- 240 mg/6mL
- Dosage Form
- INJECTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761240
- Drug Class
- Programmed Death Receptor-1 Blocking Antibody [EPC]
- Marketing Start
- 10/27/2023
Recall History
No Recall HistoryFrequently Asked Questions
What is LOQTORZI used for?
LOQTORZI contains toripalimab-tpzi. It is a injection taken intravenous. Consult your doctor for specific uses.
Is LOQTORZI a controlled substance?
LOQTORZI is not classified as a controlled substance by the DEA.
What is the generic name for LOQTORZI?
The generic name for LOQTORZI is toripalimab-tpzi. There are no other listed brand versions of toripalimab-tpzi.
What is the NDC code for LOQTORZI 240 mg/6mL?
The NDC (National Drug Code) for LOQTORZI 240 mg/6mL is 70114-340, listed by Coherus Oncology, Inc..
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)